DOCSLIB.ORG

Death by HDAC Inhibition in Synovial Sarcoma Cells Aimee N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Death by HDAC Inhibition in Synovial Sarcoma Cells Aimee N Published OnlineFirst September 6, 2017; DOI: 10.1158/1535-7163.MCT-17-0397 Small Molecule Therapeutics Molecular Cancer Therapeutics Death by HDAC Inhibition in Synovial Sarcoma Cells Aimee N. Laporte1, Neal M. Poulin1, Jared J. Barrott2, Xiu Qing Wang1, Alireza Lorzadeh3, Ryan Vander Werff4, Kevin B. Jones2, T. Michael Underhill4, and Torsten O. Nielsen1 Abstract Conventional cytotoxic therapies for synovial sarcoma pro- group targets were reactivated, including tumor suppressor vide limited benefit,andnodrugsspecifically targeting the CDKN2A, and proapoptotic transcriptional patterns were causative SS18-SSX fusion oncoprotein are currently available. induced. Functional analyses revealed that ROS-mediated Histone deacetylase (HDAC) inhibition has been shown in FOXO activation and proapoptotic factors BIK, BIM, and BMF previous studies to disrupt the synovial sarcoma oncoprotein were important to apoptosis induction following HDAC inhi- complex, resulting in apoptosis. To understand the molecular bition in synovial sarcoma. HDAC inhibitor pathway activa- effects of HDAC inhibition, RNA-seq transcriptome analysis tion results in apoptosis and decreased tumor burden follow- fl/fl was undertaken in six human synovial sarcoma cell lines. ing a 7-day quisinostat treatment in the Pten ;hSS2 mouse HDAC inhibition induced pathways of cell-cycle arrest, neu- model of synovial sarcoma. This study provides mechanistic ronal differentiation, and response to oxygen-containing spe- support for a particular susceptibility of synovial sarcoma to cies, effects also observed in other cancers treated with this HDAC inhibition as a means of clinical treatment. Mol Cancer class of drugs. More specific to synovial sarcoma, polycomb Ther; 16(12); 2656–67. Ó2017 AACR. Introduction Current cytotoxic therapies, including doxorubicin and ifo- sphamide, provide limited benefit for synovial sarcoma patients. Synovial sarcoma is an aggressive soft tissue malignancy that Following surgery and radiation, patients remain at high risk for primarily affects adolescents and young adults (1). It is charac- both early and late metastases, and despite the use of multimodal terized by the driving chimeric oncoprotein SS18-SSX, derived therapies the mortality rate remains approximately 50% within 10 from the t(X;18)(p11.2;q11.2) translocation (2). The SS18-SSX years of diagnosis (6). Thus, there is a significant need for targeted fusion oncoprotein has been proposed to interact in place of therapies against synovial sarcoma. native SS18, leading to aberrant SWI/SNF–mediated transcrip- Histone deacetylase (HDAC) inhibition has been shown to tion (3), and to act as a nidus for abnormal assembly of elicit apoptosis in synovial sarcoma models, as well as to disrupt polycomb group members (PcG) and transcription factors that SS18-SSX–mediated repressive complexes (4, 7). This inhibition lead to transcriptional repression by EZH2-mediated H3K27 was observed to elicit reactivation of repressed gene targets, trimethylation (4). Expression of tumor suppressor genes including CDKN2A (4, 7, 8). As a result, a phase II study of a EGR1 and CDKN2A has been shown to be directly repressed pan-HDAC inhibitor, pracinostat, was initiated in translocation- by SS18-SSX, whereas the antiapoptotic protein BCL2 is char- associated sarcomas, from which stable disease was achieved in acteristically upregulated (5) leading to a proliferative and three of three assessable SS18-SSX–positive patients (9). While antiapoptotic phenotype. this study had to be terminated prematurely due to unexpected interruptions in the supply of the studied compound, initial results did warrant further investigation. 1Faculty of Medicine, Vancouver Coastal Health Research Institute, University of Histone acetylation status is an important element in the British Columbia, Vancouver, British Columbia, Canada. 2Huntsman Cancer regulation of gene expression. HDAC inhibition has been Institute, University of Utah, Salt Lake City, Utah. 3Department of Microbiology shown to induce cell-cycle arrest (10), senescence (11), differ- and Immunology, Michael Smith Laboratories Centre for High-Throughput entiation (12), and apoptosis (13) in cancer cells, generally Biology, University of British Columbia, Vancouver, British Columbia, Canada. 4 leading to a decrease in tumor burden (14). While maintaining Department of Cellular and Physiological Sciences, Biomedical Research Cen- some pathway commonalities, the distinct mechanism of tre, University of British Columbia, Vancouver, British Columbia, Canada. HDAC inhibitor–induced cell death may be specifictothe Note: Supplementary data for this article are available at Molecular Cancer underlying oncogenic context. With efficacy observed in revers- Therapeutics Online (http://mct.aacrjournals.org/). ing the abnormal epigenetic status of several cancer subtypes, a Corresponding Author: Torsten O. Nielsen, University of British Columbia, 855 variety of HDAC inhibitors are currently under clinical inves- W. 12th Avenue, Vancouver, British Columbia V5Z 1M9, Canada. Phone: 604-875- tigation. Since 2006, five clinical drugs have been approved as 4111, ext. 62649; Fax: 604-875-5707; E-mail: [email protected] treatments for advanced T-cell lymphoma or multiple myeloma, doi: 10.1158/1535-7163.MCT-17-0397 while several additional HDAC-inhibiting compounds are cur- Ó2017 American Association for Cancer Research. rently under investigation in solid tumor clinical trials (14). 2656 Mol Cancer Ther; 16(12) December 2017 Downloaded from mct.aacrjournals.org on September 30, 2021. © 2017 American Association for Cancer Research. Published OnlineFirst September 6, 2017; DOI: 10.1158/1535-7163.MCT-17-0397 HDAC Inhibition in Synovial Sarcoma Cells Quisinostat (15), used in this study, is a second-generation Reads of quality 10 or greater were enumerated on the sense HDAC inhibitor showing promising efficacy against synovial strand for the exonic regions of each gene. Fragments Per Kilobase sarcoma in preclinical experiments (16). of exon per Million mapped reads (FPKM) values were calculated Although strong and specific responses to HDAC inhibition using the robust normalization method of DESeq2, and variance have been consistently observed in synovial sarcoma, the mech- stabilized log fold changes were calculated using the regularized anism of apoptosis induction remains unclear. Advancing under- log transformation of DESeq2 (24). DESeq2 was used to deter- standing of this relationship may lead to improved targeted mine significance values for differential expression between trea- therapy development and improved trial design, as well as aid ted and untreated cells, specifying pairwise comparison of drug in further elucidating the important pathways implicated in effects across cell lines. A significance threshold of 0.01 was synovial sarcoma oncogenesis. In this study, we used next-gen- selected for adjusted P values. Gene enrichment analyses were eration sequencing analyses of six human synovial sarcoma cell performed for gene ontologies using PANTHER with Bonferroni lines to investigate the mechanisms of induced cell-cycle arrest correction (25), and for the MsigDB (molecular signatures data- and cell death in synovial sarcoma following HDAC inhibition by base) v5.2 (26) using the hypergeometric test. quisinostat, a relatively new, orally available HDAC inhibitor that Raw count data for the TCGA sarcoma dataset were obtained was the top hit in a synovial sarcoma drug screen (16). from Genomic Data Commons (https://gdc.cancer.gov/node/ 31). FPKM, log2 fold changes, and significance values were deter- Materials and Methods mined using DESeq2, comparing synovial sarcoma to all other sarcoma types. Cell culture and chemicals The following human synovial sarcoma cell lines were kindly Public microarray studies provided: SYO-1 (ref. 17; Dr. Akira Kawai, National Cancer Centre The gene expression ominibus was surveyed for studies of Hospital, Tokyo, Japan, 2004), FUJI (ref. 18; Dr. Kazuo Naga- HDAC inhibition at lethal doses in cancer cell lines, and five shima, Hokkaido University School of Medicine, Sapporo, Japan, studies on more recent microarray platforms were selected for 2003), YaFuss (19), and HS-SY-II (ref.20; Dr. Marc Ladanyi, comparison [prostatic adenocarcinoma: GSE74418, neuroblas- Memorial Sloan Kettering Cancer Centre, New York, NY, toma: GSE49158, NUT midline carcinoma: GSE18668, ovarian 2014), MoJo (ref. 21; Dr. K. Jones, University of Utah, Salt Lake carcinoma GSE53603, atypical teratoid rhabdoid tumor (AT/RT): City, UT, 2014), and Yamato-SS (ref. 22; Dr. K. Itoh, Osaka GSE37373]. Expression data were downloaded from the pro- Medical Center for Cancer and Cardiovascular Diseases, Japan, cessed data files supplied to Gene Expression Omnibus (GEO; 2013). Sarcoma cell lines were maintained in RPMI1640 medium series matrix files), and differential expression was determined supplemented with 10% FBS (Life Technologies) and the presence using uniform criteria for each study using Limma (27). Gene IDs of a disease-defining SS18-SSX fusion oncogene was confirmed by were mapped to the RNA-seq dataset using the supplied platform RT-PCR analysis. Mycoplasma testing was undertaken every six specifications. Expression data for GEO studies was ranked weeks by RT-PCR analysis and any cell lines found positive were according to log fold change of treatment versus control, and 2 discarded. All cells were grown at 37 C, 95% humidity, and 5% Gene Set Enrichment Analysis (GSEA version 2.2.3) was used to CO2. Pharmacologic
Load more

Recommended publications
  • The Impact of Chromosomal Translocation Locus and Fusion Oncogene Coding Sequence in Synovial Sarcomagenesis
    Oncogene (2016) 35, 5021–5032 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-9232/16 www.nature.com/onc ORIGINAL ARTICLE The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis KB Jones1,2,3, JJ Barrott1,2,3, M Xie4, M Haldar5, H Jin1,2,3, J-F Zhu1,2,3, MJ Monument1,3, TL Mosbruger3,6, EM Langer5, RL Randall1,3, RK Wilson4,7,8,9, BR Cairns2,3,10, L Ding4,7,8,9 and MR Capecchi5 Synovial sarcomas are aggressive soft-tissue malignancies that express chromosomal translocation-generated fusion genes, SS18-SSX1 or SS18-SSX2 in most cases. Here, we report a mouse sarcoma model expressing SS18-SSX1, complementing our prior model expressing SS18-SSX2. Exome sequencing identified no recurrent secondary mutations in tumors of either genotype. Most of the few mutations identified in single tumors were present in genes that were minimally or not expressed in any of the tumors. Chromosome 6, either entirely or around the fusion gene expression locus, demonstrated a copy number gain in a majority of tumors of both genotypes. Thus, by fusion oncogene coding sequence alone, SS18-SSX1 and SS18-SSX2 can each drive comparable synovial sarcomagenesis, independent from other genetic drivers. SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences overall. In direct tumorigenesis comparisons, SS18-SSX2 was slightly more sarcomagenic than SS18-SSX1, but equivalent in its generation of biphasic histologic features. Meta-analysis of human synovial sarcoma patient series identified two tumor–gentoype–phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18-SSX2 tumors.
    [Show full text]
  • Synovial Sarcoma: Recent Discoveries As a Roadmap to New Avenues for Therapy
    Published OnlineFirst January 22, 2015; DOI: 10.1158/2159-8290.CD-14-1246 REVIEW Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for Therapy Torsten O. Nielsen 1 , Neal M. Poulin 1 , and Marc Ladanyi 2 ABSTRACT Oncogenesis in synovial sarcoma is driven by the chromosomal translocation t(X,18; p11,q11), which generates an in-frame fusion of the SWI/SNF subunit SS18 to the C-terminal repression domains of SSX1 or SSX2. Proteomic studies have identifi ed an integral role of SS18–SSX in the SWI/SNF complex, and provide new evidence for mistargeting of polycomb repression in synovial sarcoma. Two recent in vivo studies are highlighted, providing additional support for the importance of WNT signaling in synovial sarcoma: One used a conditional mouse model in which knock- out of β-catenin prevents tumor formation, and the other used a small-molecule inhibitor of β-catenin in xenograft models. Signifi cance: Synovial sarcoma appears to arise from still poorly characterized immature mesenchymal progenitor cells through the action of its primary oncogenic driver, the SS18–SSX fusion gene, which encodes a multifaceted disruptor of epigenetic control. The effects of SS18–SSX on polycomb-mediated gene repression and SWI/SNF chromatin remodeling have recently come into focus and may offer new insights into the basic function of these processes. A central role for deregulation of WNT–β-catenin sig- naling in synovial sarcoma has also been strengthened by recent in vivo studies. These new insights into the the biology of synovial sarcoma are guiding novel preclinical and clinical studies in this aggressive cancer.
    [Show full text]
  • A Novel FISH Assay for SS18–SSX Fusion Type in Synovial Sarcoma
    Laboratory Investigation (2004) 84, 1185–1192 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $30.00 www.laboratoryinvestigation.org A novel FISH assay for SS18–SSX fusion type in synovial sarcoma Cecilia Surace1,2, Ioannis Panagopoulos1, Eva Pa˚lsson1, Mariano Rocchi2, Nils Mandahl1 and Fredrik Mertens1 1Department of Clinical Genetics, Lund University Hospital, Lund, Sweden and 2DAPEG, Section of Genetics, University of Bari, Bari, Italy Synovial sarcoma is a morphologically, clinically and genetically distinct entity that accounts for 5–10% of all soft tissue sarcomas. The t(X;18)(p11.2;q11.2) is the cytogenetic hallmark of synovial sarcoma and is present in more than 90% of the cases. It produces three types of fusion gene formed in part by SS18 from chromosome 18 and by SSX1, SSX2 or, rarely, SSX4 from the X chromosome. The SS18–SSX fusions do not seem to occur in other tumor types, and it has been shown that in synovial sarcoma a clear correlation exists between the type of fusion gene and histologic subtype and, more importantly, clinical outcome. Previous analyses regarding the type of fusion genes have been based on PCR amplification of the fusion transcript, requiring access to good- quality RNA. In order to obtain an alternative tool to diagnose and follow this malignancy, we developed a fluorescence in situ hybridization (FISH) assay that could distinguish between the two most common fusion genes, that is, SS18–SSX1 and SS18–SSX2. The specificity of the selected bacterial artificial chromosome clones used in the detection of these fusion genes, as well as the sensitivity of the analysis in metaphase and interphase cells, was examined in a series of 28 synovial sarcoma samples with known fusion gene status.
    [Show full text]
  • Intrinsic Disorder of the BAF Complex: Roles in Chromatin Remodeling and Disease Development
    International Journal of Molecular Sciences Article Intrinsic Disorder of the BAF Complex: Roles in Chromatin Remodeling and Disease Development Nashwa El Hadidy 1 and Vladimir N. Uversky 1,2,* 1 Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd. MDC07, Tampa, FL 33612, USA; [email protected] 2 Laboratory of New Methods in Biology, Institute for Biological Instrumentation of the Russian Academy of Sciences, Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, Pushchino, 142290 Moscow Region, Russia * Correspondence: [email protected]; Tel.: +1-813-974-5816; Fax: +1-813-974-7357 Received: 20 September 2019; Accepted: 21 October 2019; Published: 23 October 2019 Abstract: The two-meter-long DNA is compressed into chromatin in the nucleus of every cell, which serves as a significant barrier to transcription. Therefore, for processes such as replication and transcription to occur, the highly compacted chromatin must be relaxed, and the processes required for chromatin reorganization for the aim of replication or transcription are controlled by ATP-dependent nucleosome remodelers. One of the most highly studied remodelers of this kind is the BRG1- or BRM-associated factor complex (BAF complex, also known as SWItch/sucrose non-fermentable (SWI/SNF) complex), which is crucial for the regulation of gene expression and differentiation in eukaryotes. Chromatin remodeling complex BAF is characterized by a highly polymorphic structure, containing from four to 17 subunits encoded by 29 genes. The aim of this paper is to provide an overview of the role of BAF complex in chromatin remodeling and also to use literature mining and a set of computational and bioinformatics tools to analyze structural properties, intrinsic disorder predisposition, and functionalities of its subunits, along with the description of the relations of different BAF complex subunits to the pathogenesis of various human diseases.
    [Show full text]
  • On the Role of Chromosomal Rearrangements in Evolution
    On the role of chromosomal rearrangements in evolution: Reconstruction of genome reshuffling in rodents and analysis of Robertsonian fusions in a house mouse chromosomal polymorphism zone by Laia Capilla Pérez A thesis submitted for the degree of Doctor of Philosophy in Animal Biology Supervisors: Dra. Aurora Ruiz-Herrera Moreno and Dr. Jacint Ventura Queija Institut de Biotecnologia i Biomedicina (IBB) Departament de Biologia Cel·lular, Fisiologia i Immunologia Departament de Biologia Animal, Biologia Vegetal i Ecologia Universitat Autònoma de Barcelona Supervisor Supervisor PhD candidate Aurora Ruiz-Herrera Moreno Jacint Ventura Queija Laia Capilla Pérez Bellaterra, 2015 A la mare Al pare Al mano “Visto a la luz de la evolución, la biología es, quizás, la ciencia más satisfactoria e inspiradora. Sin esa luz, se convierte en un montón de hechos varios, algunos de ellos interesantes o curiosos, pero sin formar ninguna visión conjunta.” Theodosius Dobzhansky “La evolución es tan creativa. Por eso tenemos jirafas.” Kurt Vonnegut This thesis was supported by grants from: • Ministerio de Economía y Competitividad (CGL2010-15243 and CGL2010- 20170). • Generalitat de Catalunya, GRQ 1057. • Ministerio de Economía y Competitividad. Beca de Formación de Personal Investigador (FPI) (BES-2011-047722). • Ministerio de Economía y Competitividad. Beca para la realización de estancias breves (EEBB-2011-07350). Covers designed by cintamontserrat.blogspot.com INDEX Abstract 15-17 Acronyms 19-20 1. GENERAL INTRODUCTION 21-60 1.1 Chromosomal rearrangements
    [Show full text]
  • Global Chromatin Changes Resulting from Single-Gene Inactivation—The Role of SMARCB1 in Malignant Rhabdoid Tumor
    cancers Article Global Chromatin Changes Resulting from Single-Gene Inactivation—The Role of SMARCB1 in Malignant Rhabdoid Tumor Colin Kenny 1, Elaine O’Meara 2, Mevlüt Ula¸s 2 , Karsten Hokamp 3 and Maureen J. O’Sullivan 1,2,4,* 1 School of Medicine, Trinity College, University of Dublin, Dublin 2, Ireland; [email protected] 2 The National Children’s Research Centre, O’Sullivan Research Laboratory, Oncology Division, Gate 5, Children’s Health Ireland at Crumlin, D12N512 Dublin, Ireland; [email protected] (E.O.); [email protected] (M.U.) 3 School of Genetics and Microbiology, Trinity College, University of Dublin, Dublin 2, Ireland; [email protected] 4 Histology Laboratory, Pathology Department, Children’s Health Ireland at Crumlin, D12N512 Dublin, Ireland * Correspondence: [email protected] Simple Summary: Malignant rhabdoid tumors (MRT), one of the most lethal, treatment-resistant human cancers, arises in young children within brain, kidney, liver and/or soft tissues. Generally, cancer arises in older adults, and results from multiple significant changes (mutations) accumulating in the genetic blueprint (DNA) of a person’s tissues. This blueprint is composed of a 4-letter alphabet. Together, the multiple significant changes in the blueprint then allow a cell to go “out of control”, becoming a cancer cell. The striking thing about MRT is that it has only a single spelling change, so that mutation must be very powerful to lead to such a lethal cancer. Using a model system that we developed, we show herein how this single mutation alters how the whole of the DNA is arranged, Citation: Kenny, C.; O’Meara, E.; Ula¸s,M.; Hokamp, K.; O’Sullivan, thereby having its profound and lethal effects.
    [Show full text]
  • A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2018 A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family Linda Molla Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Linda Molla June 2018 © Copyright by Linda Molla 2018 A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY Linda Molla, Ph.D. The Rockefeller University 2018 APOBEC2 is a member of the AID/APOBEC cytidine deaminase family of proteins. Unlike most of AID/APOBEC, however, APOBEC2’s function remains elusive. Previous research has implicated APOBEC2 in diverse organisms and cellular processes such as muscle biology (in Mus musculus), regeneration (in Danio rerio), and development (in Xenopus laevis). APOBEC2 has also been implicated in cancer. However the enzymatic activity, substrate or physiological target(s) of APOBEC2 are unknown. For this thesis, I have combined Next Generation Sequencing (NGS) techniques with state-of-the-art molecular biology to determine the physiological targets of APOBEC2. Using a cell culture muscle differentiation system, and RNA sequencing (RNA-Seq) by polyA capture, I demonstrated that unlike the AID/APOBEC family member APOBEC1, APOBEC2 is not an RNA editor. Using the same system combined with enhanced Reduced Representation Bisulfite Sequencing (eRRBS) analyses I showed that, unlike the AID/APOBEC family member AID, APOBEC2 does not act as a 5-methyl-C deaminase.
    [Show full text]
  • A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction
    Author Manuscript Published OnlineFirst on June 2, 2021; DOI: 10.1158/2159-8290.CD-20-1219 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. SMARCB1 in Synovial Sarcomagenesis 1 A role for SMARCB1 in synovial sarcomagenesis reveals that SS18-SSX induces canonical BAF destruction Jinxiu Li*1,2,3, Timothy S. Mulvihill*2,3, Li Li1,2,3, Jared J. Barrott1,2,3, Mary L. Nelson1,2,3, Lena Wagner6, Ian C. Lock1,2,3, Amir Pozner1,2,3, Sydney Lynn Lambert1,2,3, Benjamin B. Ozenberger1,2,3, Michael B. Ward3,4, Allie H. Grossmann3,4, Ting Liu3,4, Ana Banito6, Bradley R. Cairns2,3,5† and Kevin B. Jones1,2,3† 1Department of Orthopaedics, 2Department of Oncological Sciences, 3Huntsman Cancer Institute, 4Department of Pathology, 5Howard Hughes Medical Institute, University of Utah, Salt Lake City, Utah. 6Hopp Children’s Cancer Center (KiTZ), German Cancer Research Center (DFKZ), Heidelberg, Germany. *These authors contributed equally to this work. †These authors are co-corresponding authors. Please Address Correspondence to: Kevin B. Jones and Bradley R. Cairns Address: 2000 Circle of Hope Drive, Salt Lake City, UT 84112 Phone: 801-585-0300 Fax: 801-585-7084 Email: [email protected], [email protected] Running Title: SMARCB1 in Synovial Sarcomagenesis Key Words: SWI/SNF; Chromatin Remodeling; Mouse Genetic Model; Epigenetics; Biochemistry Financial Support: This work was supported by R01CA201396 (Jones and Cairns), U54CA231652 (Jones, Cairns, and Banito), and 2P30CA042014-31, from the National Cancer Institute (NCI/NIH), as well as the Paul Nabil Bustany Fund for Synovial Sarcoma Research (Jones), and the Sarcoma Foundation of America (Barrott).
    [Show full text]
  • Xo PANEL DNA GENE LIST
    xO PANEL DNA GENE LIST ~1700 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes (at 400 -500x average coverage on tumor) Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11
    [Show full text]
  • Primepcr™Assay Validation Report
    PrimePCR™Assay Validation Report Gene Information Gene Name synovial sarcoma translocation gene on chromosome 18-like 1 Gene Symbol SS18L1 Organism Human Gene Summary Synovial sarcomas occur most frequently in the extremities around large joints. More than 90% of cases have a recurrent and specific chromosomal translocation t(X;18)(p11.2;q11.2) in which the 5-prime end of the SS18 gene (MIM 600192) is fused in-frame to the 3-prime end of the SSX1 (MIM 312820) SSX2 (MIM 300192) or SSX4 (MIM 300326) gene. The SS18L1 gene is homologous to SS18. Gene Aliases CREST, KIAA0693, LP2261, MGC26711, MGC78386 RefSeq Accession No. NC_000020.10, NT_011362.10 UniGene ID Hs.154429 Ensembl Gene ID ENSG00000184402 Entrez Gene ID 26039 Assay Information Unique Assay ID qHsaCEP0025086 Assay Type Probe - Validation information is for the primer pair using SYBR® Green detection Detected Coding Transcript(s) ENST00000331758, ENST00000421564, ENST00000370848 Amplicon Context Sequence ATGTTGAGCAAAGCTTAGGCCAACATGAATTGTTTGTGAAGTGTGGTTGATGGTG CTTTGTTTTTTTCTGACTACTTCTATGGAAGGCCAGTGAAGAAGCAAAGGAAGA Amplicon Length (bp) 79 Chromosome Location 20:60756836-60756944 Assay Design Exonic Purification Desalted Validation Results Efficiency (%) 98 R2 0.9992 cDNA Cq 20.19 cDNA Tm (Celsius) 79 gDNA Cq 25 Page 1/5 PrimePCR™Assay Validation Report Specificity (%) 100 Information to assist with data interpretation is provided at the end of this report. Page 2/5 PrimePCR™Assay Validation Report SS18L1, Human Amplification Plot Amplification of cDNA generated from 25 ng of universal
    [Show full text]
  • The Chromatin Landscape of Primary Synovial Sarcoma Organoids Is Linked to Specific Epigenetic Mechanisms and Dependencies
    Published Online: 23 December, 2020 | Supp Info: http://doi.org/10.26508/lsa.202000808 Downloaded from life-science-alliance.org on 25 September, 2021 Research Article The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies Gaylor Boulay3,4,*, Luisa Cironi1,2,* , Sara P Garcia3,†, Shruthi Rengarajan3,†, Yu-Hang Xing3, Lukuo Lee3, Mary E Awad3, Beverly Naigles3 , Sowmya Iyer3, Liliane C Broye1,2, Tugba Keskin1,2, Alexandra Cauderay1,3, Carlo Fusco1,2, Igor Letovanec1, Ivan Chebib3, Petur Gunnalugur Nielsen3,Stephane´ Tercier6 ,Stephane´ Cherix5 , Tu Nguyen-Ngoc7 , Gregory Cote8 , Edwin Choy8 , Paolo Provero9,10 , Mario L Suva` 3,4, Miguel N Rivera3,4, Ivan Stamenkovic1,2 , Nicolo` Riggi1,2 Synovial sarcoma (SyS) is an aggressive mesenchymal malig- Introduction nancy invariably associated with the chromosomal transloca- tion t(X:18; p11:q11), which results in the in-frame fusion of the Synovial sarcoma (SyS) is the second most common soft tissue BAF complex gene SS18 to one of three SSX genes. Fusion of SS18 malignancy in the adolescent and young adult population, in which it to SSX generates an aberrant transcriptional regulator, which, in comprises 10–20% of all soft tissue sarcomas (Nielsen et al, 2015). Its permissive cells, drives tumor development by initiating major defining genetic feature is the chromosomal translocation t(X:18; p11: chromatin remodeling events that disrupt the balance between q11), which generates fusions between the nearly entire coding BAF-mediated gene activation and polycomb-dependent re- sequence of the SS18 gene and a portion of an SSX gene family pression. Here, we developed SyS organoids and performed member (SSX1 and SSX2 being the two most commonly implicated genome-wide epigenomic profiling of these models and mes- [Nielsen et al, 2015; Riggi et al, 2018]).
    [Show full text]
  • Interplay Between SWI/SNF, Nurd, and Polycomb in Chromatin Regulation and Cancer
    Downloaded from genesdev.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press SPECIAL SECTION: REVIEW Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer Adrian P. Bracken,1 Gerard L. Brien,1 and C. Peter Verrijzer2 1Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland; 2Department of Biochemistry, Erasmus University Medical Center, 3000 DR Rotterdam, the Netherlands Changes in chromatin structure mediated by ATP-depen- regulation of its replication, repair, and transcription. In dent nucleosome remodelers and histone modifying fact, the most pertinent consequence of packaging geno- enzymes are integral to the process of gene regulation. mic DNA into chromatin is that nucleosomes can impede Here, we review the roles of the SWI/SNF (switch/sucrose access of DNA-binding proteins, such as transcription fac- nonfermenting) and NuRD (nucleosome remodeling and tors. Consequently, chromatin remodeling constitutes a deacetylase) and the Polycomb system in chromatin regu- fundamental level of gene expression control. lation and cancer. First, we discuss the basic molecular Central to chromatin organization, ATP-dependent mechanism of nucleosome remodeling, and how this con- chromatin remodeling enzymes (remodelers) are molecu- trols gene transcription. Next, we provide an overview of lar motors dedicated to the assembly, positioning, or dis- the functional organization and biochemical activities of ruption of nucleosomes (Becker and Workman 2013; SWI/SNF, NuRD, and Polycomb complexes. We describe Clapier et al. 2017). By modulating the presentation of how, in metazoans, the balance of these activities is cen- DNA, chromatin remodelers provide a fundamental level tral to the proper regulation of gene expression and cellu- of gene expression control.
    [Show full text]